Trial Profile
A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-weekly), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Completed Studies CDP870-031 or CDP870-032
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Registrational
- Acronyms PRECiSE 3
- Sponsors UCB Pharma SA
- 19 Oct 2015 Results presented at the American College of Gastroenterology (ACG) 2015 Annual Scientific Meeting, as per UCB media release.
- 16 May 2015 Results presented at Digestive Disease Week 2015, according to a UCB media release.
- 06 May 2014 The results of separate post-hoc analysis of the PRECiSE 3 data evaluating long-term outcomes in Crohn's disease, stratified by patients with prior anti-TNF exposure versus bio-naive patients were presented at the Digestive Disease Week 2014.